NanoString Technologies Names John Sowatsky Vice President of Product Development
"We are very pleased to add John to the management team," said H. Perry Fell, Ph.D., Chairman and Chief Executive Officer, NanoString Technologies, Inc. "His proven track record at Affymetrix has led to the successful development and launch of many integrated biomolecular analysis systems and NanoString will see tremendous benefit from his experience as we move toward commercialization of our technology."
“We are very pleased to add John to the management team”
"The development of DNA microarray technology over a decade ago fundamentally changed the way that researchers examine the genome and has led to increased understanding of the relationship between genes and human health," said John Sowatsky. "I believe that NanoString Technologies is the next wave of disruptive technology poised to take research to a higher level of understanding not possible today."
John Sowatsky brings to NanoString over 15 years of industry experience in engineering and product development. Most recently he served as Vice President of System Business Unit at Affymetrix where he was responsible for instrument and software products totaling between $80M-100M in revenue annually. John joined Affymetrix in 1995 where over the next 10 years he gained broad technical and commercial management experience as Manager and Director of Software Development, Vice President of Software Development and Chip Design, and Vice President of Informatics and Instrumentation, overseeing a diverse team of up to 150 engineers and mathematicians responsible for the delivery of all commercial microarray designs for a broad range of genomic applications as well as the core system products such as a confocal microscope scanner, chip autoloader, and liquid handling and fluid delivery instruments used to process microarrays. Previous to Affymetrix, John held positions at Abbott Laboratories in several divisions including Diagnostics and Hospital Products and at LifeScan, a Johnson&Johnson company, where he led a team of engineers that successfully launched two blood glucose monitoring products requiring FDA 510(k) approval.
About NanoString Technologies, Inc.
NanoString Technologies is an early-stage company developing a patent-pending nanotechnology-based platform for high-speed, highly multiplexed, single molecule identification and digital quantification. This breakthrough has the potential to become a biological operating system onto which many biomolecular analysis applications can be developed. NanoString Technologies is headquartered in Seattle, Washington. For more information, visit: www.nanostring.com.